Nifedipine vs Telmisartan on Prevention of Atrial Fibrillation (AF) Recurrence in Hypertensive Patients With AF
Launched by THE SECOND AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY · Sep 15, 2011
Trial Information
Current as of June 25, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Documented hypertensive patients with paroxysmal atrial fibrillation: ECG documentation of atrial fibrillation at least in one ECG recorded during the last 2 months prior to randomization plus additional ECG recording of sinus rhythm at least 12 hours after the above mentioned ECG documentation.
- • Patients with hypertensive history were at least 5 years. Systolic pressure \> 140mmHg, \< 190mmHg, Diastolic pressure \> 85mmHg. \< 110mmHg.
- • 40 \< Age \< 65 years
- Exclusion Criteria:
- • Strong clinical evidence for therapy with AT II/ACE inhibitors before 3 months of screening
- • Therapy with antiarrhythmic agents of class I or class III within the last month, therapy with amiodarone within the last 3 months
- • Direct current (DC) cardioversion within the last 3 months
- • Symptomatic bradycardia
- • Implanted pacemaker or implanted cardioverter/defibrillator with any antitachycardiac algorithm in use
- • Cardiac surgery or cardiac catheter ablation within the last 3 months
- • Typical angina pectoris symptoms at rest or during exercise
- • Known coronary artery disease with indication for intervention
- • Valvular disease \> II degree
- • Left ventricular ejection fraction \< 40%
- • Diastolic blood pressure \> 110mm Hg at rest
- • Symptomatic arterial hypotension
- • Known renal artery stenosis
- • Serum creatinine \> 1.8 mval/l
- • Relevant hepatic or pulmonary disorders
- • Hyperthyroidism manifested clinically and in laboratory
- • Known drug intolerance for AT II inhibitors
- • Females who are pregnant or breast feeding
- • Females of childbearing potential who are not using a scientifically accepted method of contraception
- • Participation in a clinical trial within the last 30 days
- • Drug addiction or chronic alcohol abuse
- • Legal incapacity, or other circumstances which would prevent the patient from understanding the aim, nature or extent of the clinical study
- • Evidence of an uncooperative attitude
About The Second Affiliated Hospital Of Chongqing Medical University
The Second Affiliated Hospital of Chongqing Medical University is a leading healthcare institution dedicated to advancing medical research and patient care through innovative clinical trials. As a prominent academic hospital in China, it combines cutting-edge medical technology with a strong emphasis on education and training for healthcare professionals. The hospital is committed to conducting high-quality, ethically sound clinical research that contributes to the development of new therapies and enhances healthcare outcomes. With a multidisciplinary team of experts, the Second Affiliated Hospital fosters collaboration and strives to address critical health challenges through rigorous scientific investigation.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chongqing, Chongqing, China
Patients applied
Trial Officials
Yuehui Yin, MD
Study Chair
The Second Affiliated Hospital of Chongqing Medical University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials